Neuroprotection Market Insights: Size, Share, Growth Analysis & Forecast (2024-2029)
The market report presents a thorough analysis segmented by Product (Antioxidants, Apoptosis Inhibitors, Anti-Inflammatory Agents, Other Products); by Route of Administration (Oral, Intravenous); by Application (Neurodegenerative Diseases, Stroke and Ischemic Injury, Traumatic Brain Injury (TBI), Others); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).
Outlook
- The neuroprotection market is estimated to be at USD 39,323.33 Mn in 2024 and is anticipated to reach USD 57,062.22 Mn in 2029.
- The neuroprotection market is registering a CAGR of 7.73% during the forecast period of 2024-2029.
- The neuroprotection market is experiencing significant growth due to the increasing prevalence of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and stroke. Technological advancements are pushing the development of innovative neuroprotective treatments, including stem cell therapies, gene therapies, and biologics.
Request a free sample.
Ecosystem
- The participants in the global neuroprotection industry are leading the market through continuous innovation and the development of neuroprotective drugs.
- These companies are heavily investing in R&D to develop new neuroprotective therapies, strategic partnerships between pharmaceutical and biotech companies, and new product launches to maintain a competitive edge in the market.
- Several important entities in the neuroprotection market include AbbVie, Inc.; Eli Lily and Co.; Sanofi Group Novartis AG; Pfizer, Inc.; and others.
Ask for customization.
Findings
| Attributes | Values |
|---|---|
| Historical Period | 2018-2022 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Market Size (2024) | USD 39,323.33 Mn |
| Market Size (2029) | USD 57,062.22 Mn |
| Growth Rate | 7.73% CAGR from 2024 to 2029 |
| Key Segments | Product (Antioxidants, Apoptosis Inhibitors, Anti-Inflammatory Agents, Other Products); Route of Administration (Oral, Intravenous); Application (Neurodegenerative Diseases, Stroke and Ischemic Injury, Traumatic Brain Injury (TBI), Others); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa) |
| Key Vendors | AbbVie, Inc.; Eli Lily and Co.; Sanofi Group; Novartis AG; Pfizer, Inc. |
| Key Countries | The US; Canada; Mexico; Brazil; China; India; The UK; Germany; Russia; Italy; Spain; South Africa |
| Largest Market | North America |
Get a free quote.
Trends
- Increased Research in Biomarkers: There is a growing emphasis on identifying biomarkers for neurodegenerative diseases to aid in early diagnosis and tailored neuroprotective treatments. In 2023, Roche invested in research on biomarkers for Alzheimer’s disease, enabling the development of more targeted neuroprotective therapies.
- Stem Cell Research: Stem cell therapy is gaining traction as a potential neuroprotective approach. In 2023, Neuralstem Inc. initiated human trials using stem cells to treat spinal cord injuries, reflecting the ongoing innovation in this space.
- Rise of Personalized Neuroprotective Therapies: Personalized medicine is making its way into neuroprotection, focusing on individual genetic profiles to tailor treatments. In 2023, GlaxoSmithKline introduced a personalized neuroprotective therapy for patients with genetic predispositions to Parkinson’s disease.
Speak to analyst.
Catalysts
- Prevalence of Neurodegenerative Diseases: The increasing incidence of neurodegenerative diseases is a primary driver of the neuroprotection market. In 2023, the Alzheimer’s Association reported that over 55 million people worldwide are living with dementia, leading to a surge in demand for neuroprotective therapies.
- Investment in Neuroscience R&D: Investment in neuroscience research and development is increasing as pharmaceutical companies seek to discover new neuroprotective drugs. In 2023, Novartis invested $2 billion in neuroprotection research, focusing on treatments for Huntington’s disease and ALS.
- Favorable Regulatory Support: Regulatory bodies are offering accelerated approval pathways for neuroprotective drugs, encouraging market growth. In 2023, the FDA granted fast-track status to Neurocrine Biosciences for a novel neuroprotective therapy targeting tardive dyskinesia.
Inquire before buying.
Restraints
- High Development Cost: The cost of developing neuroprotective drugs is prohibitively high, especially due to the complexity of clinical trials and R&D efforts. In 2023, Eisai Co., a leading neuroprotection company, reported spending over $1.2 billion on R&D for Alzheimer’s disease treatments.
- Slow Drug Approval Process: The regulatory approval process for neuroprotective drugs is slow, often delaying the availability of new treatments. In 2023, AstraZeneca experienced delays in getting FDA approval for its neuroprotective drug due to stringent safety and efficacy requirements.
- Ethical Concerns in Clinical Trials: Conducting clinical trials for neuroprotection presents ethical concerns, particularly regarding patient safety in experimental therapies. In 2023, Neuronetics, a leader in neuroprotective device development, faced public scrutiny after reports of adverse effects in a trial for its brain stimulation device.
Personalize this research.
Hotspot
Explore purchase options.
Table of Contents
| 1.       Introduction 1.1.    Research Methodology 1.2.    Scope of the Study 2.       Market Overview / Executive Summary 2.1.    Global Neuroprotection Market (2018 – 2022) 2.2.    Global Neuroprotection Market (2023 – 2029) 3.       Market Segmentation 3.1.    Global Neuroprotection Market by Product 3.1.1. Antioxidants 3.1.2. Apoptosis Inhibitors 3.1.3. Anti-Inflammatory Agents 3.1.4. Other Products 3.2.    Global Neuroprotection Market by Route of Administration 3.2.1. Oral 3.2.2. Intravenous 3.3.    Global Neuroprotection Market by Application 3.3.1. Neurodegenerative Diseases 3.3.2. Stroke and Ischemic Injury 3.3.3. Traumatic Brain Injury (TBI) 3.3.4. Others 4.       Regional Segmentation 4.1.    North America 4.1.1. The US 4.1.2. Canada 4.1.3. Mexico 4.2.    South America 4.2.1. Brazil 4.2.2. Argentina 4.2.3. Colombia 4.2.4. Chile 4.2.5. Rest of South America 4.3.    Asia Pacific 4.3.1. China 4.3.2. India 4.3.3. Japan 4.3.4. South Korea 4.3.5. Rest of Asia Pacific 4.4.    Europe 4.4.1. The UK 4.4.2. Germany 4.4.3. Italy 4.4.4. France 4.4.5. Spain 4.4.6. Rest of Europe 4.5.    The Middle East 4.5.1. Turkey 4.5.2. UAE 4.5.3. Saudi Arabia 4.5.4. Rest of the Middle East 4.6.    Africa 4.6.1. Egypt 4.6.2. South Africa 4.6.3. Rest of Africa 5.       Value Chain Analysis of the Global Neuroprotection Market 6.       Porter Five Forces Analysis 6.1.    Threats of New Entrants 6.2.    Threats of Substitutes 6.3.    Bargaining Power of Buyers 6.4.    Bargaining Power of Suppliers 6.5.    Competition in the Industry 7.       Trends, Drivers and Challenges Analysis 7.1.    Market Trends 7.1.1.    Market Trend 1 7.1.2.    Market Trend 2 7.1.3.    Market Trend 3 7.2.    Market Drivers 7.2.1.    Market Driver 1 7.2.2.    Market Driver 2 7.2.3.    Market Driver 3 7.3.    Market Challenges 7.3.1.    Market Challenge 1 7.3.2.    Market Challenge 2 7.3.3.    Market Challenge 3 8.       Opportunities Analysis 8.1.    Market Opportunity 1 8.2.    Market Opportunity 2 8.3.    Market Opportunity 3 9.       Competitive Landscape 9.1.    AbbVie, Inc. 9.2.    Eli Lily and Co. 9.3.    Sanofi Group 9.4.    Novartis AG 9.5.    Pfizer, Inc. 9.6.    Company 6 9.7.    Company 7 9.8.    Company 8 9.9.    Company 9 9.10.  Company 10 |
Know the research methodology.
Neuroprotection Market – FAQs
1. What is the current size of the neuroprotection market?
Ans. In 2024, the neuroprotection market size is $39,323.33 Mn.
2. Who are the major vendors in the neuroprotection market?
Ans. The major vendors in the neuroprotection market are AbbVie, Inc.; Eli Lily and Co.; Sanofi Group; Novartis AG; Pfizer, Inc.
3. Which segments are covered under the neuroprotection market segments analysis?
Ans. The neuroprotection market report offers in-depth insights into Product, Route of Administration, Application, and Geography.